BMTI—Other than the CEO, who bought about $200K worth, the other insider purchases were pretty small. Still, it’s a modest bullish signal for the share price down the line.
BMTI - Their quarterly CC was very downbeat. The processing of the EU application had been suspended indefinitely and they pushed announcing the canadian augment injectable trial results to the 2nd half of 2012. The company also seemed very uncertain that reanalysis of the augment trial data would be good enough to even submit to the FDA. They will end the year with about 30-40 million. I think this would have been a decent bet with an impending EU decision but since the application has been suspended indefinitely and its trading above cash its a lot more risky to hold.
The CEO also bought about 100K of shares in may of 2011 when the share price was ~8.
News 
Market Data 
Discover 
AI
